[Duokangjiasu combined with radiotherapy in the treatment of 32 nasopharyngeal carcinoma (NPC) patients].
The results of 32 NPC patients treated by duokangjiasu combined with radiotherapy or radiotherapy alone are reported. Subjects were divided into two groups, combined and control groups with 16 patients each. The results showed that the patients treated with combination of duokangjiasu and radiotherapy had less decrease in blood IgM level than the controls treated with radiotherapy alone. Therefore, it indicates that duokangjiasu may stabilized immune function in vivo at a normal level and remarkably accelerate the resolution or eradication of the primary focus in the nasopharynx.
Li
Q Q
QQ
First Hospital, Jiangxi Medical College, Nanchang.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D004365:Drugs, Chinese Herbal; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*
D000276:Adjuvants, Immunologic; D004365:Drugs, Chinese Herbal; D007075:Immunoglobulin M; C059907:duokangjiasu